{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T07:01:35Z","timestamp":1781938895671,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.jacl.2013.10.006","type":"journal-article","created":{"date-parts":[[2013,11,9]],"date-time":"2013-11-09T03:30:17Z","timestamp":1383967817000},"page":"69-76","source":"Crossref","is-referenced-by-count":40,"title":["Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: A subanalysis of the USAGE study"],"prefix":"10.1016","volume":"8","author":[{"given":"Matthew K.","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Maki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliot A.","family":"Brinton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2013.10.006_bib1","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1345\/aph.1R127","article-title":"Dyslipidemia: management using optimal lipid-lowering therapy","volume":"46","author":"Ito","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacl.2013.10.006_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patient--the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2013.10.006_bib3","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacl.2013.10.006_bib4","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","article-title":"Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education","volume":"7","author":"Wei","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2013.10.006_bib5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/pds.2308","article-title":"Co-administration of statins with cytochrome P450 3A4 inhibitors in a UK primary care population","volume":"21","author":"Bakhai","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jacl.2013.10.006_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.17925\/USE.2012.08.02.104","article-title":"Statin drug interactions in patients with comorbidities and on multiple medications","volume":"8","author":"Ito","year":"2012","journal-title":"US Endocrinol"},{"key":"10.1016\/j.jacl.2013.10.006_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2013.10.006_bib8","unstructured":"Epocrates. Available at: http:\/\/www.epocrates.com\/. Accessed June 1, 2012."},{"key":"10.1016\/j.jacl.2013.10.006_bib9","unstructured":"The diabetes dilemma for statin users. New York Times. March 5, 2012. Available at: http:\/\/www.nytimes.com\/2012\/03\/05\/opinion\/the-diabetes-dilemma-for-statinusers.html. Accessed March 21,\u00a02013."},{"key":"10.1016\/j.jacl.2013.10.006_bib10","doi-asserted-by":"crossref","first-page":"3669","DOI":"10.2174\/138161211798220891","article-title":"Statin discontinuation in high-risk patients: a systematic review of the evidence","volume":"17","author":"Gomez Sandoval","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacl.2013.10.006_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14740338.2011.540568","article-title":"Statin-induced myopathy: a review and update","volume":"10","author":"Abd","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jacl.2013.10.006_bib12","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1161\/01.CIR.0000032466.44170.44","article-title":"ACC\/AHA\/NHLBI Clinical Advisory on the Use and Safety of Statins","volume":"106","author":"Pasternak","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2013.10.006_bib13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.numecd.2012.04.012","article-title":"Discontinuation of statin therapy due to muscular side effects: a survey in real life","volume":"23","author":"Rosenbaum","year":"2013","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.jacl.2013.10.006_bib14","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.jacl.2013.10.006_bib15","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00228-011-1125-1","article-title":"SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia","volume":"68","author":"Santos","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2013.10.006_bib16","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.clpt.2005.07.003","article-title":"Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers","volume":"78","author":"Chung","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2013.10.006_bib17","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/sj.clpt.6100267","article-title":"Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans","volume":"83","author":"Choi","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2013.10.006_bib18","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/jamia.2010.007609","article-title":"Ability of pharmacy clinical decision-support software to alert users about clinically important drug-drug interactions","volume":"18","author":"Saverno","year":"2011","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.jacl.2013.10.006_bib19","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.amjcard.2006.04.014","article-title":"Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial)","volume":"98","author":"Lloret","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2013.10.006_bib20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ahj.2011.03.032","article-title":"Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial","volume":"162","author":"Albert","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2013.10.006_bib21","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clpt.2005.06.013","article-title":"Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment","volume":"78","author":"Lee","year":"2005","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287413003061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287413003061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,10]],"date-time":"2018-10-10T19:21:21Z","timestamp":1539199281000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287413003061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1933287413003061"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2013.10.006","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}